Compare NWN & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWN | STOK |
|---|---|---|
| Founded | 1859 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2018 | 2019 |
| Metric | NWN | STOK |
|---|---|---|
| Price | $53.35 | $36.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $54.33 | $39.20 |
| AVG Volume (30 Days) | 182.4K | ★ 687.2K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | 36.45 | ★ 92.73 |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,289,363,000.00 | $184,420,000.00 |
| Revenue This Year | $11.37 | N/A |
| Revenue Next Year | $4.46 | $77.49 |
| P/E Ratio | $19.52 | ★ N/A |
| Revenue Growth | 11.83 | ★ 404.50 |
| 52 Week Low | $39.29 | $8.30 |
| 52 Week High | $55.99 | $40.22 |
| Indicator | NWN | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 48.48 | 58.53 |
| Support Level | $45.72 | $30.34 |
| Resistance Level | $53.61 | $39.00 |
| Average True Range (ATR) | 1.01 | 1.77 |
| MACD | -0.23 | 0.34 |
| Stochastic Oscillator | 21.19 | 84.76 |
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in three reportable business segments, which are NWN Gas Utility, SiEnergy, and NWN Water. The company generates maximum revenue from NWN Gas Utility segment. It also generates revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.